Insurance Coverage Lags as Cancer Science, Treatment Move Forward
“Brain cancer” or “H4 G34-mutant”? As knowledge about genetics advances, some doctors say cancers should be defined by their mutations, not the tissues where they manifest.
Health Industry
21-40 of 4,021 results
-
-
As Health Insurance Costs Soar, Healthcare Workers Also Feel the Pinch
Like many Americans, Joshua and Ashley Durham saw their health insurance premiums rise by hundreds of dollars a month this year. Despite being healthcare practitioners all too aware of the risks, they chose to go uninsured. Others, though, can’t afford to go without.
-
It’s Hard To Predict Who Will Be Suicidal. It’s Easier To Ensure People Can’t Shoot Themselves.
Some mental health experts favor suicide prevention steps that are applied broadly, with protections that aren’t tied to an individual’s specific risk.
-
The Drugs and Devices Have Been on the Market for Years. But FDA-Ordered Studies Still Aren’t Done.
To get drugs and devices out faster, the FDA lets companies conduct studies of safety or efficacy after the products are approved. In many cases, such “postmarket” studies are behind schedule or overdue, records show.
The Health Risks of AI
Episode 463Reports from a top AI company that it found and stopped attempted uses of its product to manufacture a potential bioweapon caught the attention of lawmakers in Washington this week. Meanwhile, President Trump wants to send $500 checks to about a million Obamacare enrollees. Anna Edney of Bloomberg News, Tami Luhby of CNN, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews Sabrina Corlette of the Georgetown University Center on Health Insurance Reforms.
-
3 Common Drugs Older Adults Might Be Overusing
Not all older people need benzodiazepines, antibiotics, or daily aspirin — and taking them can carry increased risks.
By Paula Span -
States Bet Big on Rural Health Startups, With a Silicon Valley Twist
States are spending rural health dollars on tech startups, betting that untested companies will succeed where doctors have vanished and hospitals have collapsed. Louisiana’s call for innovative technology drew more than 200 pitches, seeking from $250,000 to $3 million in seed money.
-
A Cancer Survivor Hoped To Work — Then She Lost Her Medicaid Disability Coverage
As state governments grapple with how to determine who’s sick enough to be excused from new Medicaid work requirements, some families are already struggling with what illnesses guarantee health coverage because of a disability.
The Meltdown in Employer-Sponsored Health Insurance
Season 16, Episode 1Stat reporter Bob Herman joins “An Arm and a Leg” to discuss the impact of surging health insurance costs on businesses and their workers.
-
Indigenous Groups Are Exempt From Medicaid Work Rules, but Native Hawaiians Aren’t
Native Hawaiians will have to comply with the new work requirements in President Donald Trump’s signature One Big Beautiful Bill Act, despite facing significant obstacles to employment and healthcare.
By Ashley Mizuo -
Nonprofits Are Helping Musicians Pay for Insurance in Austin, Texas, and Beyond
A nonprofit and a local public health agency are subsidizing marketplace health insurance for Austin music artists, even as shifting marketplace conditions make the program a more expensive proposition. It’s becoming a model for other cities and sectors.
-
A NY Hospital Tried To Close Its Birthing Center. This City United To Fight Back.
Democrats and Republicans in Troy, New York, joined together to challenge a national Catholic health system determined to close the last birthing center in the county.
-
Democrats Demand Trump Administration Halt Collection of Patients’ ER Records
Senate and House Democrats say the Trump administration’s plan to collect patients’ medical data violates privacy and will discourage people from seeking medical care.
-
Trump and Kennedy’s Health Industry Deals Haven’t Been Enforced and Are at Risk of Vanishing
The agreements, covering issues like drug pricing, reducing the use of synthetic food dyes, and cutting back on insurance prior authorization rules, were announced with fanfare and touted as victories. But it’s not clear whether they’ll result in lasting change.
-
$50B Rural Health Transformation Program Needs More Transparency, Groups Say
States must submit Rural Health Transformation Program progress reports to the federal government, but they aren’t required to proactively post those reports, or related information, publicly.
-
California Weighs Penalties for Healthcare Providers That Don’t Rein In Costs
About half of U.S. adults say they can’t afford healthcare. California is among at least eight states that have set spending growth targets for the healthcare sector. It may soon impose enforcement penalties aimed at pushing hospitals and other providers to meet those goals.
-
Watch: Mark Cuban Says You Can’t Fix Healthcare Until Every Price Is Known
With his online pharmacy, Mark Cuban changed how generic drugs are sold — and he has thoughts about how to fix the healthcare system. The billionaire businessman talks to KFF Health News’ Julie Rovner to answer the question: “How Would You Fix It?”
By Julie Rovner and Hannah Norman -
How Louisiana’s New Surgeon General Wants To Transform Public Health
Evelyn Griffin is pushing for more emphasis on wellness and prevention. She has also aligned with the MAHA movement in fighting government mandates and questioning the safety of some vaccines.
Headless FDA Gets a New Nominee
Episode 460President Trump is nominating Heidi Overton, a physician and White House policy adviser, to lead the FDA, which has been without a Senate-confirmed leader since May. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine, Shefali Luthra of The 19th, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss this story and more. Also this week, Rovner interviews billionaire businessman Mark Cuban.
-
How Much of a Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages
Patients and researchers point to evidence that many cancer drug dosages are excessive, and that reducing the amount and frequency could save billions of dollars and prevent some of the worst side effects.
By Arthur Allen